Pharmaceutical Patent Expirations Through 2016 - Drugs.com
Patent expirations up to 2016 will reduce brand spending in worldwide developed markets by $127 billion, but will be counterbalanced by generic spending, resulting in a five-year global savings of close to $106 billion
Weeklys sup SM sup Options - Cboe Options Exchange
Expirations for Weeklys. Equity, ETF, and ETN Weeklys. In November of 2012, Cboe and C2 issued Information Circulars IC12-093 and IC12-015 announcing the expansion of the number of Weeklys that can be listed for certain securities. Cboe and C2 may now list up to five consecutive Weeklys in a class provided that an expiration does not coincide with one that already exists.
Expiration Date - Investopedia
The expiration date of a derivative is the last day that an options or futures contract is valid.
DrugPatentWatch - Make Better Decisions
Make Better Decisions Business Intelligence on Biologic and Small Molecule Drugs Litigation • Prices • Patents • Drugs in Development Try a Free Trial
Condiments & Oils - StillTasty
StillTasty.com has comprehensive information about storing condiments and oils.
Drug Patent Expirations: $190 Billion Is Up for Grabs
According to estimates by Evaluate Pharma, a whopping $120 billion in sales was lost to patent expirations between 2009 and 2014.
Search for a Practitioner. This information is best viewed with Netscape 7.0, Internet Explorer 6.0 or Firefox 1.0. Enter your search criteria and click 'Search' to see the results.
Listings/Expirations Calendar - CME Group
This calendar provides a list of relevant dates for CME Group products, including listing and expiration dates.
Driver Record Dashboard - State of Idaho
Build a list of Idaho driver licenses to monitor for changes. Purchase driver's license records at any time individually or in bulk. Your records are checked twice a month (early and mid-month) for new convictions and suspensions.
Patent Expirations Of Crestor And Zetia And The Impact On ...
John LaMattina, Contributor I cover news on drugs and R&D in the pharma industry Opinions expressed by Forbes Contributors are their own. The end of 2015 saw a number of stories hailing the productivity of the biopharmaceutical industry for another great year in producing new FDA approved drugs. All ...